Trim II for Noninvasive Lipolysis and Circumference Reduction of Abdomen.

Exclusion Criteria

• •\- Active electrical implant/device in any region of the body, including pacemaker or internal defibrillator
• •Permanent implant in the treated area such as metal plates, screws or silicon, metal piercing or other.
• •Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.
• •Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
• •History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
• •History of bleeding coagulopathies or use of anticoagulants except for low-dose aspirin.
• •Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
• •Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.
• •Pregnancy and nursing.
• •Poorly controlled endocrine disorders, such as Diabetes, or thyroid dysfunction and hormonal virilization.
• •Isotretinoin (Accutane) within last 6 months.
• •Any active condition in the treatment area, such as sores, Psoriasis, eczema, and rash, open lacerations, abrasions or lesions, infection in the area to be treated.
• •Any surgical procedure in the treatment area within the last 12 months or before complete healing.
• •Having received treatment with light, laser, RF, or other devices in the treated area within 2-3 weeks for non-ablative procedures, and 6-12 weeks for ablative fractional laser resurfacing (according to treatment severity) prior to treatment, except special recommendations.
• •Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session, as per the practitioner's discretion.
• •As per the investigator's discretion, refrain from treating any condition which might make it unsafe for the patient.
• •Participated in another investigational drug or device study or have completed the follow-up phase for any previous study less than 30 days prior to the first evaluation in this study.